Evaluation of curcumin-based ophthalmic nano-emulsion on atropine-induced dry eye in mice
© 2024 Published by Elsevier Ltd..
Background: One of the most efficient treatments for dry eye syndrome (DES) is to use nanocarriers as a potential delivery system. We aim to evaluate curcumin in a nano emulsion formulation.
Methods: A new formulation containing 5.5% curcuminoid was used. DLS, Zeta potential, TEM, and HPLC tests were performed to determine the size and morphology. First, 30 mice were selected as atropine-induced dry eye models. Next, 25 mice in 5 groups were treated with the nano emulsion at different doses, and corneal tissues were separated for evaluation.
Results: The DLS test results were indicative of the particles' stability. Nano curcumin appeared to be thoroughly effective in all groups, with the highest dose showing the most similarity to the healthy control group.
Conclusions: Curcumin-based nano emulsion eye drop is a promising candidate for DES management. However, further investigation is required to evaluate the possible risks in humans.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
---|---|
Enthalten in: |
Heliyon - 10(2024), 7 vom: 15. Apr., Seite e29009 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Hadipour Jahromy, Mahsa [VerfasserIn] |
---|
Links: |
---|
Themen: |
Atropine-induced dry eye |
---|
Anmerkungen: |
Date Revised 25.04.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.1016/j.heliyon.2024.e29009 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM370909569 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM370909569 | ||
003 | DE-627 | ||
005 | 20240425233847.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240411s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.heliyon.2024.e29009 |2 doi | |
028 | 5 | 2 | |a pubmed24n1386.xml |
035 | |a (DE-627)NLM370909569 | ||
035 | |a (NLM)38601632 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Hadipour Jahromy, Mahsa |e verfasserin |4 aut | |
245 | 1 | 0 | |a Evaluation of curcumin-based ophthalmic nano-emulsion on atropine-induced dry eye in mice |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 25.04.2024 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a © 2024 Published by Elsevier Ltd. | ||
520 | |a Background: One of the most efficient treatments for dry eye syndrome (DES) is to use nanocarriers as a potential delivery system. We aim to evaluate curcumin in a nano emulsion formulation | ||
520 | |a Methods: A new formulation containing 5.5% curcuminoid was used. DLS, Zeta potential, TEM, and HPLC tests were performed to determine the size and morphology. First, 30 mice were selected as atropine-induced dry eye models. Next, 25 mice in 5 groups were treated with the nano emulsion at different doses, and corneal tissues were separated for evaluation | ||
520 | |a Results: The DLS test results were indicative of the particles' stability. Nano curcumin appeared to be thoroughly effective in all groups, with the highest dose showing the most similarity to the healthy control group | ||
520 | |a Conclusions: Curcumin-based nano emulsion eye drop is a promising candidate for DES management. However, further investigation is required to evaluate the possible risks in humans | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Atropine-induced dry eye | |
650 | 4 | |a Mice | |
650 | 4 | |a Nano emulsion | |
650 | 4 | |a Nanocurcumin | |
700 | 1 | |a Qomi, Mahnaz |e verfasserin |4 aut | |
700 | 1 | |a Fazelipour, Simin |e verfasserin |4 aut | |
700 | 1 | |a Sami, Nafiseh |e verfasserin |4 aut | |
700 | 1 | |a Faali, Farzaneh |e verfasserin |4 aut | |
700 | 1 | |a Karimi, Mehrnaz |e verfasserin |4 aut | |
700 | 1 | |a Adhami Moghadam, Farhad |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Heliyon |d 2015 |g 10(2024), 7 vom: 15. Apr., Seite e29009 |w (DE-627)NLM255913095 |x 2405-8440 |7 nnns |
773 | 1 | 8 | |g volume:10 |g year:2024 |g number:7 |g day:15 |g month:04 |g pages:e29009 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.heliyon.2024.e29009 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 10 |j 2024 |e 7 |b 15 |c 04 |h e29009 |